Innovative roadmaps for sustainable antimicrobial resistance interventions
Gianmarco Gasperini, Silvia Rossi Paccani, Karen O’Dwyer, David M. Aanensen, Darius P. H. Armstrong-James, Francesco Berlanda Scorza, David E. Bloom, Christopher J. Burns, Madalina Elena Carter-Timofte, Felipe J. Colón‐González, Shampa Das, Michael N. Dudley, Philippe Denoël, Gordon Dougan, Erin M Duffy, Alison Holmes, Anders Karlén, Neil D. Pearson, Rosanna Wai Wan Peeling, Jesús Rodríguez-Manzano, J.P. Sevilla, Shiranee Sriskandan, Sumithra Subramaniam, Herbert W. Virgin, Rino Rappuoli, David Payne, Ennio De Gregorio
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Integrated strategies to combat antibiotic-resistant bacteria and fungi require innovative commercial models, new discovery platforms, standardized genomic surveillance, and streamlined clinical trials.
Together, the results provide proof of principle for mRNA-based delivery of Fc-engineered bsAb combinations to combat SARS-CoV-2 and potentially other rapidly evolving pathogens.
Anna Z. Wec, Alice Cho, Simone Pecetta and 17 more — Science Translational Medicine
LCTG-001 demonstrated broad antiviral activity against clinically relevant respiratory viruses, including respiratory syncytial virus, adenovirus, and influenza A virus.
Yona Tugg, Jann Catherine Ang, Imran Ahmed and 4 more — Science Advances
Peer-reviewed journalBold claims, read criticallyReal-world use
We propose that regimens including at least two drugs achieving bactericidal concentrations in pulmonary cavities are more likely to meet primary clinical endpoints in patients with cavitary disease.
Jacqueline P. Ernest, Annamarie E. Bustion, Anu S. Patel and 12 more — Nature Communications
Peer-reviewed journalBold claims, read criticallyReal-world use